Zydus Lifesciences Q1 Results: Profit Up 30%, Beats Estimates

Zydus Lifesciences Ltd.'s consolidated net profit rose 30% in the first quarter of fiscal 2025, surpassing analysts' estimates.

The company posted a net profit of Rs 1,420 crore in the quarter-ended June, in comparison with Rs 1,087 crore in the year-ago period, according to an exchange filing on Friday. Analysts tracked by Bloomberg had estimated a profit of Rs 1,279 crore.

• Revenue up 20.8% at Rs 6,208 crore versus Rs 5,140 crore (Bloomberg Estimate: Rs 5,869.8 crore)

• Ebitda up 37.6% at Rs 2,109 crore versus Rs 1,533 crore (Bloomberg Estimate: Rs 1,844.3 crore)

• Margin at 34% versus 29.8% (Bloomberg Estimate: 31.4%)

• Net profit up 30.6% at Rs 1,420 crore versus Rs 1,087 crore (Bloomberg Estimate: Rs 1,279.4 crore)

India Geography

• Comprises of formulations and consumer wellness businesses, that accounts for 37% of consolidated revenues.

• Registered revenues of Rs 2212.4 crore, up 15% YoY.

Formulations business

• Registered revenues increased by 12% year-on-year to Rs 1,375.8 crore.

• The business accounted for 23% of consolidated revenues.

• Branded formulations business grew faster than the market, with 13% year-on-year growth.

• In the oncology space, the company remained the fastest-growing Indian company. The company outpaced IPM in key therapies of cardiology, gynaecology, derma, respiratory, anti-infectives and super specialty therapies of oncology and nephrology.

• Share of chronic portfolio has increased consistently over the years and stood at 41.3%, which is an improvement of 430 basis points over the last three years.

Consumer Wellness business

• Revenues rose 21% year-on-year to Rs 836.6 crore.

• The business accounted for 14% of consolidated revenues.

• The growth was broad-based and largely driven by 17% volume growth.

• Personal care segment, which comprises of Nycil and EverYuthTM brands, continued to deliver robust performance with yet another quarter of strong double-digit growth.

• Food and nutrition segment witnessed recovery during the quarter and posted double-digit growth.

US formulations business

• Revenues rose 26% year-on-year and 23% sequentially to Rs 3,092.9 crore.

• The business accounted for 51% of consolidated revenues.

• Growth during the quarter was driven by new product launches and volume expansion in the base portfolio.

• Launched seven new products during the quarter.

Shares of Zydus Lifesciences were trading 1.4% higher at Rs 1,298 apiece on the BSE as of 1:14 p.m., as compared with a 0.9% advance in the benchmark Sensex.